Clinical trials recruiting for Pancreatic Neoplasm
17
Recruiting trials
45
US states with sites
14
Countries
12%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| A2B543 | 1 |
| A2B694 | 1 |
| Bevacizumab | 1 |
| Bupivacaine | 1 |
| Carboplatin | 1 |
| Hydromorphone | 1 |
| Iopamidol | 1 |
| Isotoxic High-Dose (iHD)-SBRT | 1 |
| Itraconazole | 1 |
| LY4170156 | 1 |
| Lanreotide | 1 |
| Lutetium Lu 177 Dotatate | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 5 |
| Ohio | 5 |
| Arizona | 4 |
| Minnesota | 4 |
| Missouri | 4 |
| New York | 4 |
| Florida | 3 |
| Illinois | 3 |
| Michigan | 3 |
| Tennessee | 3 |
| Washington | 3 |
| Alabama | 2 |
Top cities
Columbus, Ohio 5La Jolla, California 4St Louis, Missouri 4Grand Rapids, Michigan 3Los Angeles, California 3New York, New York 3Seattle, Washington 3Albuquerque, New Mexico 2Allentown, Pennsylvania 2Ann Arbor, Michigan 2
Self-screener
Recruiting trials
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer
- Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
- Delayed Gastric Emptying After Pancreatic Surgery
- Endocrine-exocrine Functions and Prognosis After Pancreatectomy
- Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
- Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
- Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
- MRE for Diagnosis of Pancreatic Masses
- MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
- OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
- Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Related conditions
Trials recruiting for Pancreatic Neoplasm often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Ovarian Neoplasms 18Pancreas Cancer 86Lung cancer 2180Colorectal Neoplasms 61Colorectal cancer 1359Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 12Solid Tumour 5Solid Tumor, Adult 38
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Pancreatic Neoplasm trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.